Evidence map›Paper›PMID 33745419›Full record

ArticleThe veterinary quarterly2021

Characteristics of

Taesik Yun, Yoonhoi Koo, Sanggu Kim, Wonguk Lee, Hakhyun Kim, Dongwoo Chang, Soochong Kim, Mhan-Pyo Yang, Byeong-Teck Kang

Open access · goldAbstract readCase Reports
In one paragraph

Article in The veterinary quarterly, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Case Report:Frontiers in veterinary science · 2025
    Article
  3. Review
  4. Article
  5. Prognostic role of METTL1 in glioma.Cancer cell international · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Taesik YunLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Yoonhoi KooLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Sanggu KimDepartment of Veterinary Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Wonguk LeeDepartment of Nuclear Medicine, Chungbuk National University Hospital, Cheongju, Chungbuk, South Korea.
Hakhyun KimLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Dongwoo ChangDepartment of Veterinary Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Soochong KimDepartment of Veterinary Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Mhan-Pyo YangLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Byeong-Teck KangLaboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Chungbuk National University · KRChungbuk National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 8-year-old neutered male Yorkshire Terrier dog presented with head pressing, vestibular ataxia, neck tenderness, and no oculocephalic reflex. A demarcated lesion in the pons was identified on MRI. The patient was tentatively diagnosed with a glioma and was treated with hydroxyurea plus imatinib and prednisolone. After 30 days of therapeutic treatment, the patient showed a clear improvement in neurological signs, which lasted for 1117 days. On day 569 after the initiation of treatment,

Indexed as

AnimalsAntineoplastic AgentsBrain NeoplasmsDihydroxyphenylalanineDog DiseasesDogsFluorodeoxyglucose F18GliomaHydroxyureaImatinib MesylateLarge Neutral Amino Acid-Transporter 1MalePositron-Emission TomographyPrednisoloneReceptor, Platelet-Derived Growth Factor betaAntineoplastic AgentsDihydroxyphenylalanineFluorodeoxyglucose F18fluorodopa F 18HydroxyureaImatinib MesylateLarge Neutral Amino Acid-Transporter 1PrednisoloneReceptor, Platelet-Derived Growth Factor beta18F-FDG18F-FDOPAcanineDoggliomahydroxyureaimatinibL-type amino acid transporter 1positron emission tomography

Identifiers

PMID33745419
PMCPMC8118437
OpenAlexW3138138975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.